Ads
related to: Macular Degeneration Wet- Wet AMD FAQs
Get Answers To Frequently Asked
Questions About Wet AMD
- Clinical Study Results
See The Results of A Clinical Study
To Learn More About This Treatment
- Financial Assistance
Learn About Financial Support
That May Be Available To You
- Appointment Tips
Get Tips And Useful Information
To Talk to your Retina Specialist
- Wet AMD FAQs
Search results
Roche’s VABYSMO has successful Q1 sales despite Regeneron and Bayer’s EYLEA HD launch
Pharmaceutical Technology via Yahoo Finance· 3 days agoLast week, Roche released promising first-quarter (Q1) 2024 sales figures for VABYSMO, a vascular...
Can At-Home Vision Tests Detect Active Neovascular AMD?
MedPage Today· 2 days agoThree at-home vision-monitoring tools failed to detect worsening neovascular age-related macular ...
EYLEA HD shows promise in long-term clinical trials By Investing.com
Investing.com· 4 days agoHD clinical program during a series of presentations at the Association for Research in Vision and...
Research Analysts Set Expectations for Adverum Biotechnologies, Inc.’s Q1 2024 Earnings...
ETF DAILY NEWS· 5 hours agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Free Report) – Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Adverum Biotechnologies in a note ...
...Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) -...
WTNH-TV New Haven· 4 days agoEluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development...
Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 - Ocular...
Benzinga· 3 days agoTherapeutix, Inc. OCUL "Ocular", the "Company"))), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and commercialization of innovative ...
Regeneron (REGN) Q1 Earnings, Sales Miss on Lower Eylea Sales
Zacks· 2 days agoRegeneron (REGN) reports Q1 results, wherein both the top and bottom lines miss estimates due to lower Eylea sales. Shares down.
Should You Consider Regeneron (REGN) Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 4 days agoAn increase in profits from Dupixent and further uptake of Eylea HD are likely to have aided...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends - Regeneron Pharmaceuticals...
Benzinga· 4 days agoThe company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; ...
Ads
related to: Macular Degeneration Wet
